Neil Macneale is the editor of 2-for-1 Stock Split Newsletter, a speciality advisory service in whic...
Big Biotech News Today?
03/11/2014 11:00 am EST
Shares of this biotech company were up 9.2% yesterday, March 10, because it's announcing fourth quarter results today, and MoneyShow's Jim Jubak, thinks this could be a sign of what to expect for the rest of 2014.
Shares of biotech OncoGenex (OGXI) were up 9.2% yesterday, March 10 as of 3:00 PM New York time.
Why? Because March 10 was the day before today, March 11. The company is scheduled to report fourth quarter results today, on March 11, after the close of the New York market, and speculation yesterday was that the company will announce major progress on the Phase 3 trial of custirsen, its drug for metastatic prostate cancer and for advanced non-small cell lung cancer. The company recently announced that the trial had reached the specified number of events required for final analysis and that the results would be reported as soon as they are available. The speculation is that “as soon as they are available” means before the end of March.
That's a major change from 2013 when expectations were that the final results wouldn't be released until the middle of 2014.
After hitting a low at $6.70 a share on November 6, 2013, shares of OncoGenex have climbed 107%. They are still 12.7% below the $15.71, March 14, 2012, price, where I added OncoGenex to my Jubak's Picks portfolio. But I think we're looking at news on custirsen and the company's second cancer drug apatorsen in 2014 that will finally move the stock to my $22 target price.
The Phase 3 SYNERGY trial for custirsen is a big deal for OncoGenex, since the drug represents a novel target for treating advanced prostate cancer. Success in this trial wouldn't just give the company a substantial new drug but, more importantly, it would validate the company's approach to cancer as a platform for developing other cancer drugs. It's the potential for that platform that got Teva Pharmaceuticals (TEVA) to sign on for potential milestone payments of $370 million. I expect to hear something from OncoGenex on its progress in reaching those milestones today, on March 11.
I'm also expecting to hear some news on the Phase 2 trials for apatorsen in bladder cancer. The report on the results of those trials is likely for the second half of 2014.
Speculation ahead of the fourth quarter report is that this will be the year that OncoGenex demonstrates the validity of its cancer platform. After the recent run up in the shares on that speculation, the danger is that the actual news could disappoint. I'd hold through any sell on the news dip, as long as the reports on the custirsen trials are solidly positive.
Full disclosure: I don't own shares of any of the companies mentioned in this post in my personal portfolio. When in 2010 I started the mutual fund I manage, Jubak Global Equity Fund, I liquidated all my individual stock holdings and put the money into the fund. The fund may or may not now own positions in any stock mentioned in this post. The fund did not own shares of OncoGenex as of the end of December. For a full list of the stocks in the fund see the fund's portfolio here.
Related Articles on HEALTHCARE
Headquartered in New Jersey and founded in 1891, Merck & Co. (MRK) is a global health care compa...
Novartis (NVS) is a Swiss-based pharmaceutical company formed by the merger of Basel-based Sandoz an...
LOXO Oncology (LOXO) focuses its research on cancers that are uniquely dependent on single gene abno...